MENU
+Compare
LYRA
Stock ticker: NASDAQ
AS OF
Sep 26 closing price
Price
$6.47
Change
+$0.11 (+1.73%)
Capitalization
10.64M

LYRA Lyra Therapeutics Inc Forecast, Technical & Fundamental Analysis

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients... Show more

LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for LYRA with price predictions
Sep 26, 2025

LYRA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 08, 2025

LYRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 39 cases where LYRA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 55 cases where LYRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on September 23, 2025. You may want to consider a long position or call options on LYRA as a result. In of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LYRA just turned positive on September 19, 2025. Looking at past instances where LYRA's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LYRA advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 50-day moving average for LYRA moved below the 200-day moving average on August 20, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.562) is normal, around the industry mean (19.823). P/E Ratio (0.000) is within average values for comparable stocks, (53.778). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.098). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (11.099) is also within normal values, averaging (349.540).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LYRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a clinical-stage therapeutics company, which develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
480 Arsenal Way
Phone
+1 617 393-4600
Employees
145
Web
https://lyratherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AQMS7.302.38
+48.37%
Aqua Metals Inc
LFVN10.190.20
+2.00%
Lifevantage Corp
DKS228.273.04
+1.35%
Dick's Sporting Goods
IBCP31.530.17
+0.54%
Independent Bank Corp
ICUI118.810.55
+0.47%
ICU Medical

LYRA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LYRA has been closely correlated with ROQAF. These tickers have moved in lockstep 85% of the time. This A.I.-generated data suggests there is a high statistical probability that if LYRA jumps, then ROQAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
+1.73%
ROQAF - LYRA
85%
Closely correlated
N/A
EYPT - LYRA
58%
Loosely correlated
+5.38%
VERA - LYRA
53%
Loosely correlated
+4.60%
KYMR - LYRA
51%
Loosely correlated
+4.68%
CLNN - LYRA
39%
Loosely correlated
+0.09%
More